Human anthelminthic vaccines: Rationale and challenges

Vaccine

Volumn 34, Issue 30, 2016, Pages 3549-3555

  Hotez, Peter J ^a,b,c   Strych, Ulrich ^a   Lustigman, Sara ^d   Bottazzi, Maria Elena ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b BAYLOR UNIVERSITY   (United States)

^c RICE UNIVERSITY   (United States)

^d NEW YORK BLOOD CENTER   (United States)

Author keywords

Ascariasis; Helminths; Hookworm; Neglected tropical diseases; NTDs; Shistosomiasis

Indexed keywords

ANTHELMINTHIC VACCINE; ANTHELMINTIC AGENT; UNCLASSIFIED DRUG; VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ASCARIASIS; CHILD HEALTH; CYSTICERCOSIS; ECHINOCOCCOSIS; FOOD POISONING; HELMINTHIASIS; HOOKWORM INFECTION; HUMAN; LYMPHATIC FILARIASIS; MALARIA; NONHUMAN; NOTE; ONCHOCERCIASIS; PRIORITY JOURNAL; REPRODUCTIVE HEALTH; SCHISTOSOMIASIS; TREMATODIASIS; TRICHURIASIS; DEVELOPING COUNTRY; HOOKWORM INFECTIONS; IMMUNOLOGY;

ANTHELMINTICS; DEVELOPING COUNTRIES; HELMINTHIASIS; HOOKWORM INFECTIONS; HUMANS; SCHISTOSOMIASIS; VACCINES;

EID: 84966713314     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.03.112     Document Type: Note

References (72)

1. [1] GBD_Study_2013_Collaborators, Global, regional, and national incidence, prevalence, and YLDs, for 301 acute and chronic diseases and injuries for 188 countires, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 386 (2015), 743–800.
2. [2] DALYs GBD, Collaborators H, Murray, C.J., Barber, R.M., Foreman, K.J., Ozgoren, A.A., et al. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition. Lancet 386 (2015), 2145–2191.
3. [3] GBD_Mortality_and_Causes_of_Death_Collaborators, Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385 (2015), 117–171.
4. [4] Hotez, P.J., Alvarado, M., Basanez, M.G., Bolliger, I., Bourne, R., Boussinesq, M., et al. The global burden of disease study 2010: interpretation and implications for the neglected tropical diseases. PLoS Negl Trop Dis, 8, 2014, e2865.
5. [5] Hotez, P.J., Mass drug administration and integrated control for the world's high-prevalence neglected tropical diseases. Clin Pharmacol Ther 85 (2009), 659–664.
6. [6] Molyneux, D.H., Hotez, P.J., Fenwick, A., Rapid-impact interventions: how a policy of integrated control for Africa's neglected tropical diseases could benefit the poor. PLoS Med, 2, 2005, e336.
7. [7] USAID, Neglected tropical diseases program. 2015.
8. [8] WHO, Planning, requesting medicines and reporting for preventive chemotherapy. Wkly Epidemiol Rec 90 (2015), 133–146.
9. [9] Hotez, P., Enlarging the Audacious Goal: elimination of the world's high prevalence neglected tropical diseases. Vaccine 29:Suppl. 4 (2011), D104–D110.
10. [10] Keenan, J.D., Hotez, P.J., Amza, A., Stoller, N.E., Gaynor, B.D., Porco, T.C., et al. Elimination and eradication of neglected tropical diseases with mass drug administrations: a survey of experts. PLoS Negl Trop Dis, 7, 2013, e2562.
11. [11] WHO, Progress toward eliminating onchocerciasis in the WHO Region of the Americas: verification of elimination of transmission in Mexico. Wkly Epidemiol Rec 90 (2015), 577–581.
12. [12] Ichimori, K., MDA-Lymphatic Filariasis. Trop Med Health 42 (2014), 21–24.
13. [13] McCarty, T.R., Turkeltaub, J.A., Hotez, P.J., Global progress towards eliminating gastrointestinal helminth infections. Curr Opin Gastroenterol 30 (2014), 18–24.
14. [14] Blair, P., Diemert, D., Update on prevention and treatment of intestinal helminth infections. Curr Infect Dis Rep, 17, 2015, 465.
15. [15] Gaze, S., Driguez, P., Pearson, M.S., Mendes, T., Doolan, D.L., Trieu, A., et al. An immunomics approach to schistosome antigen discovery: antibody signatures of naturally resistant and chronically infected individuals from endemic areas. PLoS Pathog, 10, 2014, e1004033.
16. [16] Barry, M.A., Simon, G.G., Mistry, N., Hotez, P.J., Global trends in neglected tropical disease control and elimination: impact on child health. Arch Dis Child 98 (2013), 635–641.
17. [17] D.O.L.F., Death to onchocerciasis and lymphatic filariasis. 2015.
18. [18] Hotez, P.J., Bottazzi, M.E., Zhan, B., Makepeace, B.L., Klei, T.R., Abraham, D., et al. The onchocerciasis vaccine for Africa—TOVA—initiative. PLoS Negl Trop Dis, 9, 2015, e0003422.
19. [19] Kim, Y.E., Remme, J.H., Steinmann, P., Stolk, W.A., Roungou, J.B., Tediosi, F., Control, elimination, and eradication of river blindness: scenarios, timelines, and ivermectin treatment needs in Africa. PLoS Negl Trop Dis, 9, 2015, e0003664.
20. [20] Makepeace, B.L., Babayan, S.A., Lustigman, S., Taylor, D.W., The case for vaccine development in the strategy to eradicate river blindness (onchocerciasis) from Africa. Expert Rev Vaccines 14 (2015), 1163–1165.
21. [21] Turner, H.C., Walker, M., Lustigman, S., Taylor, D.W., Basanez, M.G., Human onchocerciasis modelling the potential long-term consequences of a vaccination programme. PLoS Negl Trop Dis, 9, 2015, e0003938.
22. [22] Albonico, M., Bickle, Q., Ramsan, M., Montresor, A., Savioli, L., Taylor, M., Efficacy of mebendazole and levamisole alone or in combination against intestinal nematode infections after repeated targeted mebendazole treatment in Zanzibar. Bull World Health Organ 81 (2003), 343–352.
23. [23] De Clercq, D., Sacko, M., Behnke, J., Gilbert, F., Dorny, P., Vercruysse, J., Failure of mebendazole in treatment of human hookworm infections in the southern region of Mali. Am J Trop Med Hyg 57 (1997), 25–30.
24. [24] Keiser, J., Utzinger, J., Efficacy of current drugs against soil-transmitted helminth infections: systematic review and meta-analysis. JAMA 299 (2008), 1937–1948.
25. [25] Soukhathammavong, P.A., Sayasone, S., Phongluxa, K., Xayaseng, V., Utzinger, J., Vounatsou, P., et al. Low efficacy of single-dose albendazole and mebendazole against hookworm and effect on concomitant helminth infection in Lao PDR. PLoS Negl Trop Dis, 6, 2012, e1417.
26. [26] Albonico, M., Smith, P.G., Ercole, E., Hall, A., Chwaya, H.M., Alawi, K.S., et al. Rate of reinfection with intestinal nematodes after treatment of children with mebendazole or albendazole in a highly endemic area. Trans R Soc Trop Med Hyg 89 (1995), 538–541.
27. [27] Lee, B.Y., Bacon, K.M., Bailey, R., Wiringa, A.E., Smith, K.J., The potential economic value of a hookworm vaccine. Vaccine 29 (2011), 1201–1210.
28. [28] Hotez, P.J., Bethony, J.M., Diemert, D.J., Pearson, M., Loukas, A., Developing vaccines to combat hookworm infection and intestinal schistosomiasis. Nat Rev Microbiol 8 (2010), 814–826.
29. [29] Hotez, P.J., Diemert, D., Bacon, K.M., Beaumier, C., Bethony, J.M., Bottazzi, M.E., et al. The human hookworm vaccine. Vaccine 31:Suppl. 2 (2013), B227–B232.
30. [30] Zhan, B., Beaumier, C.M., Briggs, N., Jones, K.M., Keegan, B.P., Bottazzi, M.E., et al. Advancing a multivalent ‘Pan-anthelmintic’ vaccine against soil-transmitted nematode infections. Expert Rev Vaccines 13 (2014), 321–331.
31. [31] McManus, D.P., Loukas, A., Current status of vaccines for schistosomiasis. Clin Microbiol Rev 21 (2008), 225–242.
32. [32] Bergquist, N.R., Leonardo, L.R., Mitchell, G.F., Vaccine-linked chemotherapy: can schistosomiasis control benefit from an integrated approach. Trends Parasitol 21 (2005), 112–117.
33. [33] Brindley, P.J., Hotez, P.J., Break Out: urogenital schistosomiasis and Schistosoma haematobium infection in the post-genomic era. PLoS Negl Trop Dis, 7, 2013, e1961.
34. [34] You, H., McManus, D.P., Vaccines and diagnostics for zoonotic schistosomiasis japonica. Parasitology 142 (2015), 271–289.
35. [35] Chan, M.S., Woolhouse, M.E., Bundy, D.A., Human schistosomiasis: potential long-term consequences of vaccination programmes. Vaccine 15 (1997), 1545–1550.
36. [36] Mulvenna, J., Sripa, B., Brindley, P.J., Gorman, J., Jones, M.K., Colgrave, M.L., et al. The secreted and surface proteomes of the adult stage of the carcinogenic human liver fluke Opisthorchis viverrini. Proteomics 10 (2010), 1063–1078.
37. [37] Lightowlers, M.W., Control of Taenia solium taeniasis/cysticercosis: past practices and new possibilities. Parasitology 140 (2013), 1566–1577.
38. [38] Weatherhead, J.E., Hotez, P.J., Worm infections in children. Pediatr Rev 36 (2015), 341–352 quiz 53–4.
39. [39] Hotez, P., Whitham, M., Helminth infections: a new global women's health agenda. Obstet Gynecol 123 (2014), 155–160.
40. [40] Brooker, S., Hotez, P.J., Bundy, D.A., Hookworm-related anaemia among pregnant women: a systematic review. PLoS Negl Trop Dis, 2, 2008, e291.
41. [41] Kjetland, E.F., Hegertun, I.E., Baay, M.F., Onsrud, M., Ndhlovu, P.D., Taylor, M., Genital schistosomiasis and its unacknowledged role on HIV transmission in the STD intervention studies. Int J STD AIDS 25 (2014), 705–715.
42. [42] Hotez, P.J., Herricks, J.R., Helminth elimination in the pursuit of sustainable development goals: a worm index for human development. PLoS Negl Trop Dis, 9, 2015, e0003618.
43. [43] Hotez, P.J., Molyneux, D.H., Fenwick, A., Ottesen, E., Ehrlich Sachs, S., Sachs, J.D., Incorporating a rapid-impact package for neglected tropical diseases with programs for HIV/AIDS, tuberculosis, and malaria. PLoS Med, 3, 2006, e102.
44. [44] Brooker, S., Akhwale, W., Pullan, R., Estambale, B., Clarke, S.E., Snow, R.W., et al. Epidemiology of plasmodium-helminth co-infection in Africa: populations at risk, potential impact on anemia, and prospects for combining control. Am J Trop Med Hyg 77 (2007), 88–98.
45. [45] Brooker, S., Clements, A.C., Hotez, P.J., Hay, S.I., Tatem, A.J., Bundy, D.A., et al. The co-distribution of Plasmodium falciparum and hookworm among African school children. Malar J, 5, 2006, 99.
46. [46] Ndeffo Mbah, M.L., Skrip, L., Greenhalgh, S., Hotez, P., Galvani, A.P., Impact of Schistosoma mansoni on malaria transmission in Sub-Saharan Africa. PLoS Negl Trop Dis, 8, 2014, e3234.
47. [47] Metenou, S., Kovacs, M., Dembele, B., Coulibaly, Y.I., Klion, A.D., Nutman, T.B., Interferon regulatory factor modulation underlies the bystander suppression of malaria antigen-driven IL-12 and IFN-gamma in filaria-malaria co-infection. Eur J Immunol 42 (2012), 641–650.
48. [48] Metenou, S., Babu, S., Nutman, T.B., Impact of filarial infections on coincident intracellular pathogens: Mycobacterium tuberculosis and Plasmodium falciparum. Curr Opin HIV AIDS 7 (2012), 231–238.
49. [49] Ndeffo Mbah, M.L., Gilbert, J.A., Galvani, A.P., Evaluating the potential impact of mass praziquantel administration for HIV prevention in Schistosoma haematobium high-risk communities. Epidemics 7 (2014), 22–27.
50. [50] Bustinduy, A.L., Sutherland, L.J., Chang-Cojulun, A., Malhotra, I., DuVall, A.S., Fairley, J.K., et al. Age-stratified profiles of serum IL-6, IL-10, and TNF-alpha cytokines among Kenyan children with Schistosoma haematobium, Plasmodium falciparum, and other chronic parasitic co-infections. Am J Trop Med Hyg 92 (2015), 945–951.
51. [51] Mulu, A., Anagaw, B., Gelaw, A., Ota, F., Kassu, A., Yifru, S., Effect of deworming on Th2 immune response during HIV-helminths co-infection. J Transl Med, 13, 2015, 236.
52. [52] Hotez, P.J., Bottazzi, M.E., Strych, U., New vaccines for the world's poorest people. Annu Rev Med, 2015.
53. [53] Hess, J.A., Zhan, B., Bonne-Annee, S., Deckman, J.M., Bottazzi, M.E., Hotez, P.J., et al. Vaccines to combat river blindness: expression, selection and formulation of vaccines against infection with Onchocerca volvulus in a mouse model. Int J Parasitol 44 (2014), 637–646.
54. [54] Curti, E., Seid, C.A., Hudspeth, E., Center, L., Rezende, W., Pollet, J., et al. Optimization and revisions of the production process of the Necator americanus glutathione S-transferase 1 (Na-GST-1), the lead hookworm vaccine recombinant protein candidate. Hum Vaccines Immunother, 2014, 1914–1925.
55. [55] Seid, C.A., Curti, E., Jones, R.M., Hudspeth, E., Rezende, W., Pollet, J., et al. Expression, purification, and characterization of the Necator americanus aspartic protease-1 (Na-APR-1 (M74)) antigen, a component of the bivalent human hookworm vaccine. Hum Vaccines Immunother 11 (2015), 1474–1488.
56. [56] Pearson, M.S., Jariwala, A.R., Abbenante, G., Plieskatt, J., Wilson, D., Bottazzi, M.E., et al. New tools for NTD vaccines: a case study of quality control assays for product development of the human hookworm vaccine Na-APR-1M74. Hum Vaccines Immunother 11 (2015), 1251–1257.
57. [57] Tang, Y.T., Gao, X., Rosa, B.A., Abubucker, S., Hallsworth-Pepin, K., Martin, J., et al. Genome of the human hookworm Necator americanus. Nat Genet 46 (2014), 261–269.
58. [58] Riveau, G., Deplanque, D., Remoue, F., Schacht, A.M., Vodougnon, H., Capron, M., et al. Safety and immunogenicity of rSh28GST antigen in humans: phase 1 randomized clinical study of a vaccine candidate against urinary schistosomiasis. PLoS Negl Trop Dis, 6, 2012, e1704.
59. [59] Sotillo, J., Pearson, M., Becker, L., Mulvenna, J., Loukas, A., A quantitative proteomic analysis of the tegumental proteins from Schistosoma mansoni schistosomula reveals novel potential therapeutic targets. Int J Parasitol 45 (2015), 505–516.
60. [60] Pearson, M.S., Becker, L., Driguez, P., Young, N.D., Gaze, S., Mendes, T., et al. Of monkeys and men: immunomic profiling of sera from humans and non-human primates resistant to schistosomiasis reveals novel potential vaccine candidates. Front Immunol, 6, 2015, 213.
61. [61] Zhang, W., Ahmad, G., Le, L., Rojo, J.U., Karmakar, S., Tillery, K.A., et al. Longevity of Sm-p80-specific antibody responses following vaccination with Sm-p80 vaccine in mice and baboons and transplacental transfer of Sm-p80-specific antibodies in a baboon. Parasitol Res 113 (2014), 2239–2250.
62. [62] Le, L., Zhang, W., Karmakar, S., Ahmad, G., Torben, W., Siddiqui, A.A., Simultaneous priming with DNA encoding Sm-p80 and boosting with Sm-p80 protein confers protection against challenge infection with Schistosoma mansoni in mice. Parasitol Res 113 (2014), 1195–1200.
63. [63] Karmakar, S., Zhang, W., Ahmad, G., Torben, W., Alam, M.U., Le, L., et al. Use of an Sm-p80-based therapeutic vaccine to kill established adult schistosome parasites in chronically infected baboons. J Infect Dis 209 (2014), 1929–1940.
64. [64] Karmakar, S., Zhang, W., Ahmad, G., Torben, W., Alam, M.U., Le, L., et al. Cross-species protection: Schistosoma mansoni Sm-p80 vaccine confers protection against Schistosoma haematobium in hamsters and baboons. Vaccine 32 (2014), 1296–1303.
65. [65] Tendler, M., Almeida, M., Simpson, A., Development of the Brazilian anti Schistosomiasis vaccine based on the recombinant FABP Sm14 +GLA-SE. Front Immunol, 2015, 6.
66. [66] Klei TR. Efficacy studies of novel Brugia malayi homologs of Onchocerca volvulus recombinant protein vaccine candidates. Personal Communication.
67. [67] Lustigman S. Immunomic profiling of the Ov-103 and Ov-RAL-2 vaccine candidates in Onchocerca volvulus exposed people from endemic areas of Cameroon. Unpublished results.
68. [68] Hotez, P.J., Bethony, J.M., Oliveira, S.C., Brindley, P.J., Loukas, A., Multivalent anthelminthic vaccine to prevent hookworm and schistosomiasis. Expert Rev Vaccines 7 (2008), 745–752.
69. [69] Bethony, J.M., Cole, R.N., Guo, X., Kamhawi, S., Lightowlers, M.W., Loukas, A., et al. Vaccines to combat the neglected tropical diseases. Immunol Rev 239 (2011), 237–270.
70. [70] Hewitson, J.P., Maizels, R.M., Vaccination against helminth parasite infections. Expert Rev Vaccines 13 (2014), 473–487.
71. [71] WHO, WHO grants approval for safe, effective meningitis A vaccine for infants. 2015.
72. [72] Hotez, P.J., Blue marble health redux: neglected tropical diseases and human development in the group of 20 (G20) nations and Nigeria. PLoS Negl Trop Dis, 9, 2015, e0003672.